Abstract:Posthemorrhagic hydrocephalus occurs in up to 30% of infants with high-grade intraventricular hemorrhage and is associated with the worst neurocognitive outcomes in preterm infants. The mechanisms of posthemorrhagic hydrocephalus after intraventricular hemorrhage are unknown; however, CSF levels of iron metabolic pathway proteins including hemoglobin have been implicated in its pathogenesis. Here, we develop an animal model of intraventricular hemorrhage using intraventricular injection of hemoglobin at post-natal day 4 that results in acute and chronic hydrocephalus, pathologic choroid plexus iron accumulation, and subsequent choroid plexus injury at post-natal days 5, 7, and 15. This model also results in increased expression of aquaporin-1, Na+/K+/Cl- cotransporter 1, and Na+/K+/ATPase on the apical surface of the choroid plexus 24 h post-intraventricular hemorrhage. We use this model to evaluate a clinically relevant treatment strategy for the prevention of neurological sequelae after intraventricular hemorrhage using intraventricular administration of the iron chelator deferoxamine at the time of hemorrhage. Deferoxamine treatment prevented posthemorrhagic hydrocephalus for up to 11 days after intraventricular hemorrhage and prevented the development of sensorimotor gating deficits. In addition, deferoxamine treatment facilitated acute iron clearance through the choroid plexus and subsequently reduced choroid plexus iron levels at 24 h with reversal of hemoglobin-induced aquaporin-1 upregulation on the apical surface of the choroid plexus. Intraventricular administration of deferoxamine at the time of intraventricular hemorrhage may be a clinically relevant treatment strategy for preventing posthemorrhagic hydrocephalus and likely acts through promoting iron clearance through the choroid plexus to prevent hemoglobin-induced injury.

Iron Neurotoxicity and Protection by Deferoxamine in Intracerebral Hemorrhage

Deferoxamine Reduces CSF Free Iron Levels Following Intracerebral Hemorrhage

Iron As A Therapeutic Target In Intracerebral Hemorrhage: Preclinical Testing Of Deferoxamine

Iron Accumulation And Dna Damage In A Pig Model Of Intracerebral Hemorrhage

Deferasirox, a trivalent iron chelator, ameliorates neuronal damage in hemorrhagic stroke models

Deferoxamine Affects Heat Shock Protein Expression in Heart after Intracerebral Hemorrhage in Aged Rats

Efficacy of Deferoxamine in Animal Models of Intracerebral Hemorrhage: A Systematic Review and Stratified Meta-Analysis

Activation of C-Jun-n-terminal Kinase in a Rat Model of Intracerebral Hemorrhage: the Role of Iron.

Progress of the therapy of the intracerebral hemorrhage

Neuroprotection of brain-permeable iron chelator VK-28 against intracerebral hemorrhage in mice

Iron toxicity in intracerebral hemorrhage: Physiopathological and therapeutic implications

Deferoxamine Alleviates Iron Overload and Brain Injury in a Rat Model of Brainstem Hemorrhage

Deferoxamine Prevents Neonatal Posthemorrhagic Hydrocephalus Through Choroid Plexus-Mediated Iron Clearance

Deferoxamine Reduces Endothelial Ferroptosis and Protects Cerebrovascular Function after Experimental Traumatic Brain Injury

The combination of deferoxamine and minocycline strengthens neuroprotective effect on acute intracerebral hemorrhage in rats

Effect Comparison of Both Iron Chelators on Outcomes, Iron Deposit, and Iron Transporters After Intracerebral Hemorrhage in Rats

Iron and Intracerebral Hemorrhage: From Mechanism to Translation

Iron toxicity, lipid peroxidation and ferroptosis after intracerebral haemorrhage

Hemoglobin and Iron Handling in Brain after Subarachnoid Hemorrhage and the Effect of Deferoxamine on Early Brain Injury

Deferoxamine therapy for intracerebral hemorrhage: A systematic review